Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-00610355
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
PF-00610355 (also known as PF-610355) is an investigational, inhalable ultra-long acting β2-adrenoreceptor agonist (ultra-LABA) developed by Pfizer for the once-daily treatment of asthma and chronic obstructive pulmonary disease (COPD). It acts primarily in the lungs to induce bronchodilation by stimulating Beta2-adrenoreceptor, leading to relaxation of airway smooth muscle. The drug features a sulfonamide agonist headgroup that confers high intrinsic crystallinity and may support a zwitterionic form in the solid state. Pharmacokinetic optimization aimed to minimize systemic exposure after inhalation, reducing systemically mediated adverse events. Clinical studies reached up to phase II for COPD and asthma but development was discontinued around 2011 for strategic and regulatory reasons.
- Other names
- 862541-45-5ZH5SMU97AJZH-5SMU97AJZH 5SMU97AJ
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on PF-00610355.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-00610355.